ErbB receptors and signaling pathways in cancer
- PMID: 19208461
- DOI: 10.1016/j.ceb.2008.12.010
ErbB receptors and signaling pathways in cancer
Abstract
The ErbB receptor tyrosine kinases play important roles in normal physiology and in cancer. Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clinical studies suggest that they play roles in cancer development and progression. These receptors have been intensely studied, not only to understand the mechanisms underlying their oncogenic potential, but also to exploit them as therapeutic _targets. ErbB receptors activate a multiplicity of intracellular pathways via their ability to interact with numerous signal transducers. Furthermore, there are now many ErbB-_targeted inhibitors used in the clinic. In this review we will concentrate on breast tumors with ERBB2 gene amplification/receptor overexpression and non-small cell lung cancer (NSCLC) with activating EGFR mutations. We will discuss data showing the important role that the PI3K/Akt pathway plays, not only in cancer development, but also in response to _targeted therapies. Finally, mechanisms contributing to resistance to ErbB-_targeted therapeutics will also be discussed.
Similar articles
-
The efficacy of ErbB receptor-_targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.Cancer Res. 2002 Jun 1;62(11):3151-8. Cancer Res. 2002. PMID: 12036928
-
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.Cancer Res. 2005 Dec 1;65(23):11018-25. doi: 10.1158/0008-5472.CAN-05-0491. Cancer Res. 2005. PMID: 16322251
-
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.Exp Cell Res. 2005 Apr 1;304(2):604-19. doi: 10.1016/j.yexcr.2004.12.008. Epub 2005 Jan 21. Exp Cell Res. 2005. PMID: 15748904
-
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
-
_targeting the EGFR and the PKB pathway in cancer.Curr Opin Cell Biol. 2009 Apr;21(2):185-93. doi: 10.1016/j.ceb.2008.12.006. Epub 2009 Feb 11. Curr Opin Cell Biol. 2009. PMID: 19216065 Review.
Cited by
-
Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma.Tumour Biol. 2015 Aug;36(8):5931-42. doi: 10.1007/s13277-015-3268-7. Epub 2015 Feb 28. Tumour Biol. 2015. PMID: 25724187
-
Flexible _targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Mol Med. 2012 May 9;18(1):565-76. doi: 10.2119/molmed.2011.00493. Mol Med. 2012. PMID: 22354215 Free PMC article.
-
Identification of genes associated with renal cell carcinoma using gene expression profiling analysis.Oncol Lett. 2016 Jul;12(1):73-78. doi: 10.3892/ol.2016.4573. Epub 2016 May 16. Oncol Lett. 2016. PMID: 27347102 Free PMC article.
-
Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells.J Cancer. 2023 Oct 16;14(18):3477-3495. doi: 10.7150/jca.88446. eCollection 2023. J Cancer. 2023. PMID: 38021158 Free PMC article.
-
The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.Sci Rep. 2016 Oct 24;6:35850. doi: 10.1038/srep35850. Sci Rep. 2016. PMID: 27775011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
